WebIdiopathic pulmonary fibrosis is a fatal lung disease characterized by progressive and excessive accumulation of myofibroblasts and in the lung. Connective-tissue growth … WebNov 1, 2024 · CTGF, a protein localized in the extracellular matrix, is a driver of fibrotic tissue remodeling as a consequence of an aberrant wound healing process. Over-expression of this target in lung tissue is observed in patients suffering from IPF, and clinical data indicate inhibition of CTGF reduces the decline in lung function among these patients.
Pancreatic Cancer Action Network Partners With FibroGen To …
WebMay 3, 2012 · In patients with IPF, CTGF levels are elevated in plasma, 8 in transbronchial biopsy specimens, and in bronchoalveolar lavage fluid. 9 Increased levels of CTGF have also been observed in experimental models of lung fibrosis. 10 In addition, CTGF can cause susceptibility to experimentally-induced lung fibrosis in otherwise resistant mice. WebJun 16, 2024 · FibroGen's pamrevlumab is a first-in-class antibody that inhibits the activity of connective tissue growth factor (CTGF), which, in cancer, is characterized by promotion of tumor growth. biology healthcare
Connective-Tissue Growth Factor Contributes to TGF-β1–induced …
WebNational Center for Biotechnology Information WebJul 22, 2024 · Pamrevlumab, an anti-CTGF human monoclonal antibody, is advancing towards Phase 3 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF) and pancreatic cancer, and is currently in a Phase 2 trial for Duchenne muscular dystrophy (DMD). FibroGen is also developing a biosynthetic cornea in China. WebAs CTGF is a secreted protein, monoclonal antibodies are an option as blockade agents. The most advanced trials are of treatment with FG-3019/ pamrevlumab, a humanized anti-CTGF antibody, which has been tested in the clinic for muscular dystrophy, pancreatic cancer, liver fibrosis, idiopathic pulmonary fibrosis, and type 1 and 2 diabetes [3]. dailymotion relaxing music